This article is brought to you by the new Cannabis Commerce + Chemistry Podcast.
Welcome to Cannabis Conclusions, a unique educational series from Higher Learning LV that is targeted at hemp and cannabis industry professionals. This series provides readers with the conclusion section from important modern peer-reviewed research studies.
A 2019 study conducted at TU Dortmund University in Germany and entitled "Minor Cannabinoids of Cannabis Sativa L." that was published in the Journal of Medical Science explored the "often neglected minor cannabinoids and discuss biosynthetic and chemical degradation routes to other neglected cannabinoids in Cannabis sativa starting from THCA, CBDA, and cannabichromenic acid (CBCA)."
Study Conclusions
"After the legislation of Cannabis sativa L. for medical use, research and development is exploding and still huge amounts of investments take place to push pharmacological studies. After only five years of legalised research in the USA, Israel, Canada, and Germany, we merely can see the tip of the iceberg and more research in the interest of both the patient and consumer is welcome and needed.
"If we can see today a great interest in THC‑C5 and CBD‑C5 by industry and academia, it is more than likely that companies and scientists will focus in the near future on the unexplored world of minor cannabinoids in the near future. A limiting factor for extensive research is the low availability and high price for minor cannabinoids. Extraction and purification of these compounds from cannabis extracts is challenging due to extreme low yield and low stability during downstreaming.
"Beyond CBD and THC research and business today, expect new disruptive findings to establish minor cannabinoids in pharmacology and clinics—why the story of the one‑billion‑dollar plant is not told yet."
"Alternative strategies like organic synthesis or biotechnological production will be attractive and competitive to plant‑based production in the future. The chemical diversity of cannabinoids is high and still unexplored, but we know that the biosynthetic impact by enzymatic catalysis on diversity was overestimated and photochemical conversion in a non‑aqueous trichome 'bioreactor' is an accepted hypothesis to explain pattern and occurrence.
"Beyond the horizon of CBD‑C5 and THC‑C5 dominated research and business today, we can expect new disruptive findings to establish minor cannabinoids in pharmacology and clinics, why the story of the one‑billion‑dollar plant is not told yet."
🎧 Like what you just read? Listen and learn with our highly educational weekly Cannabis Commerce + Chemistry Podcast. At under 30 minutes per episode, it helps industry professionals stay current on trending topics.